Journal of Clinical Lipidology

The Journal of Clinical Lipidology is growing!📈

Our 2025 CiteScore climbed to 6.8, a reflection of the high-quality research and dedicated community behind every issue.

#Lipidology #ClinicalResearch

The JCL February issue is live!📰

First in the #JCLSpotlight: A meta-analysis of 92 studies found carotid plaque in 23% of asymptomatic adults (18–65), rising from 5.2% (18–45) to 30.3% (50–65) and higher in men vs women.

Read more: https://ow.ly/qpxv50YqaC2

The NLA’s newest meta-analysis shows that in CVOTs of solely or predominantly primary prevention participants, each 1 mmol/L reduction in LDL-C was associated w/ a 30% RRR in 4-point MACE.

These findings support LDL-C lowering early in the life course: https://ow.ly/32o050YpGI4

On #WorldObesityDay, we invite you to explore the #JCLSpecialEdition on obesity, which brings together multidisciplinary insights for clinicians, researchers, educators, and public health leaders.

Read the issue: lipidjournal.com/issue/S1933-2874(26)X0002-2

#JCLSpecialEdition #Obesity

Diagnosis and management of CVD risk factors is an important aspect of an obesity management plan.

Evidence shows treatment with liraglutide, semaglutide, and/or bariatric surgery lowers CVD events and mortality.

Explore the full findings: https://ow.ly/LtnK50Yofyb

#JCLSpecialEdition #Obesity

A key characteristic of obesity is adipocytopathic atherogenic dyslipidemia. This review highlights the lipid specialist’s role in team-based obesity care to address cardiometabolic risk and improve long-term outcomes.

Read now: https://ow.ly/GOtQ50YmuEM

#JCLSpecialEdition #Obesity

Childhood obesity is a distinct condition with unique management needs. This review covers rising prevalence, genetic/environmental drivers, comorbidities & current treatments (IHBLT, metabolic surgery & pharmacotherapy).

Read now: https://ow.ly/AMmG50YlV5S

#JCLSpecialEdition #Obesity

Obesity management requires destigmatization and recognition as a chronic disease. This article highlights the role of GLP-1 RAs in achieving >10% weight loss with CV-kidney-metabolic benefits.

Read more: https://ow.ly/4QkW50Yl0Kv

NOW LIVE: #JCLSpecialEdition: Obesity as a Cardiometabolic Disease

How is obesity defined? This article evaluates the benefits and disadvantages of current and proposed measures to characterize obesity.

Read the review: https://ow.ly/xEBf50YkcVj

#JCLSpotlight: A BPA alert for patients with LDL-C ≥ 190 mg/dL increased statin use (39.4%→61.7%), reduced LDL-C by 84.1 mg/dL, and raised FH diagnoses (2.3%→6.0%). Electronic messaging may improve treatment and detection. #HeartMonth

Read more: https://ow.ly/cxPq50Yhatl

#JCLSpotlight: In a new analysis of the CLEAR Outcomes trial, adding lipid-modifying therapy after randomization did not impact the observed results of the trial.

Read more: https://ow.ly/Xi4P50YeBq2

#JCLSpotlight A pilot trial shows artichoke leaf extract reduced liver steatosis and size and improved body composition in patients with obesity and MASLD, while noting a significant transaminase increase.

🔗Read more: https://ow.ly/BXZA50Ye3e4

#JCLSpotlight: Elevated relative fat mass is strongly associated with a higher prevalence of sleep disorders in U.S. adults, highlighting adiposity as a modifiable factor in sleep health and prevention strategies.

Read more: https://ow.ly/HpRT50YbKoh

Last week, the NLA released its updated expert clinical consensus on familial hypercholesterolemia. The guidance covers refined diagnostic criteria, genetic testing, cascade screening, and updated management strategies, including therapies for HoFH and HeFH. #HeartMonth

🔗https://ow.ly/mm1w50Y90l7

#JCLSpotlight: Lomitapide effectively and safely reduced TG levels in FCS patients with prior pancreatitis over a nearly 3-year follow-up period. Results were consistent with open-label trial data despite a lower median dose, with no new safety signals observed.

🔗https://ow.ly/F0B650Y8X43

#JCLRoundtable: A European Perspective on Lipid Management & CV Health

Global experts Drs. Kausik Ray, Børge Nordestgaard, and P. Barton Duell discuss early LDL-C lowering, combination therapy, Lp(a) screening, FH, and what’s next in CV prevention.

Read the discussion: https://ow.ly/QJCH50Y544I

#JCLSpotlight: New research shows men and women have distinct inflammatory responses during long-term evolocumab therapy, highlighting the importance of sex-specific considerations in CV risk management and treatment monitoring.

Read more: https://ow.ly/Fa8B50Y3Utv

#JCLSpotlight: New research shows PCSK9 inhibitors and inclisiran significantly reduce visit-to-visit LDL-C variability vs standard therapy. Lower LDL-C variability was linked to fewer CV events, highlighting lipid stability as a key treatment goal.

Read more: https://ow.ly/qLkI50Y0Gbh

The January JCL issue is live!📘

#JCLSpotlight: A pooled analysis of phase 3 ODYSSEY studies shows that in patients with ASCVD (without prior ACS or stroke), alirocumab significantly reduced LDL-C vs placebo or ezetimibe.

Read more: https://ow.ly/QZrQ50Y0eyy

🚨Deadline Extended!🚨

You now have until January 12 at 11:59 PM ET to submit your abstract for the 2026 #NLASessions. Take advantage of this extension and make sure your research is part of the premier meeting in lipidology!

🔗Submit now: lipid.org/abstracts

#JCLSpotlight: High plasma Lp(a) is linked to increased IFN-γ–associated gene expression in classical monocytes and elevated CXCL10 in those without ASCVD, while chromatin accessibility remains unchanged across groups.

Read more: https://ow.ly/NENz50XKWcC

#JCLSpotlight: New data from the Balance study shows strong concordance between NAFCS Score ≥45 and a positive genetic diagnosis of FCS. The score can clinically support an FCS diagnosis when genetic testing isn’t available or is indeterminate.

Read more: https://ow.ly/7EBj50XKW2h

#JCLSpotlight: 2/3 of statin-intolerant patients report self-medication—often pain meds, vitamin D, electrolytes & omega-3s. None linked to lower LDL-C. Over half report negative statin messaging, highlighting the need for proactive guidance.

Read more: https://ow.ly/gcoj50XKVUj

#JCLSpotlight: Data from a phase 2b trial suggests evinacumab may help lower triglycerides in patients with sHTG and a history of sHTG-associated acute pancreatitis.

Learn more: ow.ly/h3wn50XHFVh

#JCLSpotlight: Current lipid-lowering therapies have only modest impact on Lp(a), but new RNA-targeted agents are showing promise. Pelacarsen—an antisense oligonucleotide—reduced Lp(a) by ≥80% in phase 2b and is now in multiple phase 3 trials.

Read more: ow.ly/T6Jy50XBZhz

📣NEW expert clinical review from the NLA on #FCS.

📄Read the full-length article: ow.ly/ALrc50VBAv6

Don't miss our latest JCL Roundtable!🗣️ Drs. Carol F. Kirkpatrick, Kristina S. Petersen, Michael J. Wilkinson, & Kevin C. Maki discuss dietary recommendations for #ASCVD prevention. Read the conversation👉 lipidjournal.com/article/S1933-2874(25)00052-2/fulltext #cardiosky

📢NEW NLA & AGS expert clinical consensus on managing #hypercholesterolemia in adults older than 75 years without a history of #ASCVD.

Read the article now: sciencedirect.com/science/arti...

#Cardiosky

We are excited to share our Joint Expert Clinical Consensus with @aspcardio.bsky.social! To celebrate #NationalTriglycerideDay, check out our article on Persistent Chylomicronemia. @lipidjournal.bsky.social #CardioSky

🔗 lipidjournal.com/article/S193...

🫀To kick off our #AmericanHeartMonth series, we begin with sharing our recent position statement on the importance of a lipid specialty taxonomy code. Check out some key quotes from "Lipidology: The Time is Now for Specialty Recognition", published in JCL. ➡️